DepYmed to Present at the 9th World Rett Syndrome Congress
02. Oktober 2024 09:00 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
19. März 2024 10:59 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., March 19, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
DepYmed to Meet with Investors at the BIO CEO and Investor Conference
21. Februar 2024 09:35 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
07. Februar 2024 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023
03. Oktober 2023 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Oct. 03, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Meet with Investors at the BioFuture Conference in New York City October 4-6, 2023
27. September 2023 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
15. Juni 2023 09:00 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
31. Mai 2023 09:30 ET
|
DepYmed, Inc.
FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
16. November 2022 09:35 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease
23. Mai 2022 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...